No Data
Chordia Research Memo (6): MALT1 inhibitors have been licensed out to Ono Pharmaceutical for a maximum condition of over 50 billion yen.
■Chordia Therapeutics <190A> development pipeline 2. MALT1 inhibitors (1) Mechanism of action of MALT1 inhibitors and background of early development. MALT1 inhibitors are a development pipeline expected to show therapeutic effects for refractory lymphoma, achieving early development to OncoOne in 2020 after conducting preclinical trials. In refractory lymphoma, factors in T cell signaling or B cell signaling pathways (T cell receptor CD28, B cell receptor
Chordia Research Memo (1): A biotech venture advancing the development of potential blockbuster anti-cancer drugs.
Chordia Therapeutics <190A> was founded by drug discovery researchers spun out from takeda pharmaceuticals sp adr <4502>, specializing in the development of small molecule anticancer drugs. The core business ranges from exploratory research to clinical research, with in-house manufacturing and sales through partnership strategies domestically, aiming for early profitability by licensing out overseas. Listed on the Tokyo Stock Exchange Growth Market in June 2024.
List of stocks with cleared clouds (Part 2) [Ichimoku Kinko Hyo: List of Stocks with Cleared Clouds]
List of stocks breaking through the cloud market Code Stock name End price Leading Span A Leading Span B Tokyo Stock Exchange Prime ＜1878＞ Daito Construction 17135 17693.75 17210 ＜2060＞ Feed One 855 866.75 857 ＜2264＞ Morinaga Milk 3068 3477.25 3360.5 ＜229
Ono Pharmaceutical: Confirmation letter
Ono Pharmaceutical: Half-Year Report - Term 77 (2024/04/01 - 2025/03/31)
Kinoden, Sekisui Chemical, etc. (additional) Rating
Upgrade - Bullish Code Stock Name Securities Company Previous After Change ----------------------------- <9009> Keisei Morgan S "Under W" "Equal W" Downgrade - Bearish Code Stock Name Securities Company Previous After Change ----------------------------- <7731> nikon corp spons
No Data
No Data